ATE166867T1 - Azacyclische verbindungen, sie enthaltende zusammensetzungen und ihre verwendung als tachykinin antagoniste - Google Patents

Azacyclische verbindungen, sie enthaltende zusammensetzungen und ihre verwendung als tachykinin antagoniste

Info

Publication number
ATE166867T1
ATE166867T1 AT94907565T AT94907565T ATE166867T1 AT E166867 T1 ATE166867 T1 AT E166867T1 AT 94907565 T AT94907565 T AT 94907565T AT 94907565 T AT94907565 T AT 94907565T AT E166867 T1 ATE166867 T1 AT E166867T1
Authority
AT
Austria
Prior art keywords
optionally substituted
6alkyl
pct
compounds
tachykin
Prior art date
Application number
AT94907565T
Other languages
English (en)
Inventor
Raymond Baker
Christopher John Swain
Brian John Williams
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939303243A external-priority patent/GB9303243D0/en
Priority claimed from GB939322150A external-priority patent/GB9322150D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE166867T1 publication Critical patent/ATE166867T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/42Oxygen atoms attached in position 3 or 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT94907565T 1993-02-18 1994-02-10 Azacyclische verbindungen, sie enthaltende zusammensetzungen und ihre verwendung als tachykinin antagoniste ATE166867T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939303243A GB9303243D0 (en) 1993-02-18 1993-02-18 Therapeutic agents
GB939322150A GB9322150D0 (en) 1993-10-27 1993-10-27 Therapeutic agents

Publications (1)

Publication Number Publication Date
ATE166867T1 true ATE166867T1 (de) 1998-06-15

Family

ID=26302480

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94907565T ATE166867T1 (de) 1993-02-18 1994-02-10 Azacyclische verbindungen, sie enthaltende zusammensetzungen und ihre verwendung als tachykinin antagoniste

Country Status (9)

Country Link
US (1) US5633266A (de)
EP (1) EP0683767B1 (de)
JP (1) JPH08506823A (de)
AT (1) ATE166867T1 (de)
AU (1) AU679207B2 (de)
CA (1) CA2152925A1 (de)
DE (1) DE69410784T2 (de)
ES (1) ES2116583T3 (de)
WO (1) WO1994019323A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
WO1995019344A1 (en) * 1994-01-13 1995-07-20 Merck Sharp & Dohme Limited Gem-disubstituted azacyclic tachykinin antagonists
GB9402688D0 (en) * 1994-02-11 1994-04-06 Merck Sharp & Dohme Therapeutic agents
JPH10500944A (ja) * 1994-05-05 1998-01-27 メルク シヤープ エンド ドーム リミテツド モルホリン誘導体及びタキキニンのアンタゴニストとしてのそれらの使用
DE19504627A1 (de) * 1995-02-13 1996-08-14 Bayer Ag Verfahren und neue Zwischenprodukte zur Herstellung von Triazolinonen
GB9513117D0 (en) * 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
GB9513121D0 (en) * 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
US6013631A (en) 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
MXPA02004330A (es) 1999-11-03 2004-07-30 Albany Molecular Res Inc Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
US20020016283A1 (en) * 2000-06-12 2002-02-07 Guttuso Thomas J. Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
AU7334901A (en) 2000-07-11 2002-01-21 Du Pont Pharm Co Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
US7407480B2 (en) * 2001-07-27 2008-08-05 Ams Research Corporation Method and apparatus for correction of urinary and gynecological pathologies, including treatment of incontinence cystocele
WO2003101459A1 (en) * 2002-05-29 2003-12-11 The Regents Of The University Of California Antagonizing nk1 receptors inhibits consumption of substances of abuse
BRPI0513359A (pt) 2004-07-15 2008-05-06 Amr Technology Inc tetraidroisoquinolinas substituìdas por arila e heteroarila e uso destes para bloquear a recaptação de norepinefrina, dopamina, e serotonina
WO2006030975A1 (ja) * 2004-09-17 2006-03-23 Takeda Pharmaceutical Company Limited ピペリジン誘導体およびその用途
WO2006115285A1 (ja) * 2005-04-21 2006-11-02 Takeda Pharmaceutical Company Limited 医薬組成物
EP1888050B1 (de) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs
UA95454C2 (uk) 2005-07-15 2011-08-10 Амр Текнолоджи, Інк. Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2083831B1 (de) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Verfahren zur behandlung von fettsäure-synthese-hemmern
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AR064777A1 (es) 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AU2008335788B2 (en) * 2007-12-12 2012-11-29 Amgen Inc. Glycine transporter-1 inhibitors
CN102014631A (zh) 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2429296B1 (de) 2009-05-12 2017-12-27 Albany Molecular Research, Inc. 7-([1,2,4,]triazol[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorphenyl)-1,2,3,4- tetrahydroisochinolin und seine verwendung
MX2011011901A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas.
CN102638982B (zh) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
AU2010307198B9 (en) 2009-10-14 2014-02-13 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. 低分子干渉核酸(siNA)を用いたカテニン(カドヘリン結合型タンパク質)β1(CTNNB1)遺伝子発現のRNA干渉媒介性阻害
LT2606134T (lt) 2010-08-17 2019-07-25 Sirna Therapeutics, Inc. Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
EP2608669B1 (de) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2615916B1 (de) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Kondensierte pyrazolderivate als neue erk-hemmer
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2654748B1 (de) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
EP2699568A1 (de) 2011-04-21 2014-02-26 Piramal Enterprises Limited Kristalline form eines morpholinsulfonylindolderivat-salzes und verfahren zu seiner herstellung
EP2770987B1 (de) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Neue verbindungen als erk-hemmer
EP3453762B1 (de) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Sina-zusammensetzungen
EP2900241B1 (de) 2012-09-28 2018-08-08 Merck Sharp & Dohme Corp. Neuartige verbindungen als erk-hemmer
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
EP3041938A1 (de) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Kreisförmige polynukleotide
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2025008409A2 (en) 2023-07-03 2025-01-09 Preeti Jha Substituted 2-phenylpiperidine compounds for use in the diagnosis, treatment and/or prevention of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6033439B2 (ja) * 1980-03-07 1985-08-02 財団法人相模中央化学研究所 ジペプチドの製造方法
UA41251C2 (uk) * 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
US5242930A (en) * 1991-02-11 1993-09-07 Merck Sharp & Dohme Ltd. Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
ATE136885T1 (de) * 1991-08-20 1996-05-15 Merck Sharp & Dohme Azacyclische verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
US5444074A (en) * 1992-04-15 1995-08-22 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
AU675786B2 (en) * 1992-04-15 1997-02-20 Merck Sharp & Dohme Limited Azacyclic compounds
US5496833A (en) * 1993-04-13 1996-03-05 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists

Also Published As

Publication number Publication date
AU679207B2 (en) 1997-06-26
EP0683767A1 (de) 1995-11-29
JPH08506823A (ja) 1996-07-23
US5633266A (en) 1997-05-27
WO1994019323A1 (en) 1994-09-01
AU6109394A (en) 1994-09-14
DE69410784D1 (de) 1998-07-09
ES2116583T3 (es) 1998-07-16
DE69410784T2 (de) 1999-01-14
EP0683767B1 (de) 1998-06-03
CA2152925A1 (en) 1994-09-01

Similar Documents

Publication Publication Date Title
ATE166867T1 (de) Azacyclische verbindungen, sie enthaltende zusammensetzungen und ihre verwendung als tachykinin antagoniste
DE69516853D1 (de) Aralkoxy und aralkylthio substituierte azacyclische verbindungen als tachykinin antagonisten
ATE242625T1 (de) Chelat-zubereitungen, die oximverbindungen enthalten
DE69504300D1 (de) Gem-bissubstituierte azazyclische tachykinin-antagonisten
ATE81504T1 (de) 4-mercapto-butyramide-n-mono- oder n,ndisubstituiert durch ein mono- oder polyhydroxyalkyl-radikal und ihre verwendung als reduktionsmittel zur dauernden verformung von haaren.
MXPA02011417A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas de receptores muscarinicos.
ATE188472T1 (de) 4-arylmethyloxymethyl piperidine als tachykinin antagonisten
DE69103636D1 (de) Biaromatische verbindungen und ihre anwendung in menschen- und tierheilkunde und in der kosmetik.
BG102792A (bg) Производни на заместени 4-хидроксифенилалканоилови киселини с агонистична активност към рраr-гама
MXPA02011418A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas del receptor muscarinico.
FI934366A0 (fi) Atp-analoger
GB2248449B (en) Piperazine derivatives
ATE191473T1 (de) 2,3,5-trimethyl-hydroxyanilid-derivative, ihre herstellung und ihre theraoeutische verwendung
MY113945A (en) Amino substituted pyrimidines and triazines
DE59712118D1 (de) Verwendung von nicht-peptidischen Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung und Prävention der Alzheimerischen Krankheit
ATE148741T1 (de) Reinigendes desinfektionsmittel
SE7710783L (sv) Alfa-(4-bifenylyl)-bensyl-azolium-salter till anvendning for bekempning av mikroorganismer och sett att framstella foreningarna
YU43902A (sh) Novi razgranati supstituisani amino derivati od 3-amino-1- -fenil-1h(1,2,4) triazola, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže
BR9508676A (pt) Carbamolicarboxamida composição processos para preparar compostos e a composição e para controlar fungos nocivos e uso compost e das composições
DE59807744D1 (de) Verwendung von sulfonyloxadiazolonen als mikrobizide
TW372955B (en) Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
DE50001988D1 (de) DOLLAR g(a)- DOLLAR g(a)' -SUBSTITUIERTE N-ALKYL-3-ALKENYLBENZOYL-PYRAZOL-DERIVATE
SE8205587L (sv) 1,2,3-tiadiazol-5-yl-karbamid-derivat och sett att framstella dessa foreningar samt medel, innehallande foreningarna, med tillvextreglerande och avlovande verkan
PT72244A (en) Ethers of 1-(2-propynyloxy)-2-amino-3-propanol
BG46157A3 (bg) Метод за получаване на n-алкил(ен)-n-(о,о-дву- заместен тиофосфорил- n', n' - двузаместени глицинамиди

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties